Use of recombinant factor VIIa (rFVIIa) as pre-hospital treatment in a swine model of fluid percussion traumatic brain injury

Use of recombinant factor VIIa (rFVIIa) as pre-hospital treatment in a swine model of fluid percussion traumatic brain injury

Context: Recombinant factor VIIa (rFVIIa) has been used as an adjunctive therapy for acute post-traumatic hemorrhage and reversal of iatrogenic coagulopathy in trauma patients in the hospital setting. However, investigations regarding its potential use in pre-hospital management of traumatic brain i...

Full description

Bibliographic Details
Main Authors:	Bobby Kim, Ashraful Haque, Françoise G Arnaud, Kohsuke Teranishi, Thomas Steinbach, Charles R Auker, Richard M McCarron, Daniel Freilich, Anke H Scultetus
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2014-01-01
Series:	Journal of Emergencies, Trauma and Shock
Subjects:	Coagulopathy necrosis pre-hospital rFVIIa swine traumatic brain injury
Online Access:	http://www.onlinejets.org/article.asp?issn=0974-2700;year=2014;volume=7;issue=2;spage=102;epage=111;aulast=Kim

Similar Items

Low-dose recombinant factor VIIa for massive bleeding
by: A Mordasini, et al.
Published: (2011-07-01)

Impacto da utilização do rFVIIa nas hemorragias intracranianas: Revisão da literatura
by: Daniel Damiani, et al.
Published: (2009-09-01)

Use of recombinant factor VIIa (rFVIIa) in noncoagulopathic traumatic brain injury
by: Menashe Zaaroor, et al.
Published: (2006-12-01)

BUDGET IMPACT ANALYSIS OF INHIBITOR HAEMOPHILIA A THERAPY WITH BYPASSING AGENTS
by: Konstantin Tachkov, et al.
Published: (2019-04-01)

Recombinant activated factor VII for uncontrolled bleeding postcardiac surgery
by: Aly Makram Habib, et al.
Published: (2016-10-01)

Continuous infusion of recombinant activated factor VII: a review of data in congenital hemophilia with inhibitors and congenital factor VII deficiency
by: Rajpurkar M, et al.
Published: (2018-11-01)

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence
by: Linari S, et al.
Published: (2020-05-01)

Current management of massive hemorrhage in trauma
by: Johansson Pär I, et al.
Published: (2012-07-01)

Uso del factor VII activado recombinante en pacientes no hemofílicos en Cuba Use of the recombinant activated factor VII in non-hemophilic patients in Cuba
by: Olga Agramonte Llanes, et al.
Published: (2008-12-01)

Uso del FVII activado recombinante en la enfermedad de Rendú-Osler-Weber o telangiectasia hemorrágica hereditaria y sangramiento digestivo: Primer caso comunicado en Cuba Use of recombinat activated factor VII in Rendú-Osler-Weber's disease or hereditary hemorrhagic talangiectasia and digestive bleeding: First case reported in Cuba
by: Olga M Agramonte Llanes, et al.
Published: (2008-12-01)

Successful non-standard approaches to massive hemoptysis in invasive pulmonary aspergillosis
by: Mitrović Mirjana, et al.
Published: (2012-01-01)

Uso del factor VII activado recombinante en pacientes no hemofílicos en Cuba
by: Olga Agramonte Llanes, et al.

Recombinant activated factor VII in the treatment of intractable non-surgical bleeding following major vascular procedures
by: Končar Igor B., et al.
Published: (2008-01-01)

Acquired haemophilia: a case report and a clinical review
by: Lucia Todaro, et al.
Published: (2013-04-01)

The effect of emicizumab and bypassing agents in patients with hemophilia – An in vitro study
by: Nina Haagenrud Schultz, et al.
Published: (2021-07-01)

Adaptation of recombinant activated factor VII in the treatment of acquired haemophilia A: Results from a prospective study (ACQUI-7) in France
by: Benoît Guillet, et al.
Published: (2021-01-01)

Prostasin and hepatocyte growth factor B in factor VIIa generation: Serine protease knockdowns in zebrafish
by: Gauri Khandekar, et al.
Published: (2020-10-01)

Bioengineering of rFVIIa Biopharmaceutical and Structure Characterization for Biosimilarity Assessment
by: Othman Montacir, et al.
Published: (2018-01-01)

Local pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH) &ndash; a review of a new treatment paradigm
by: Nielsen JD, et al.
Published: (2012-03-01)

Determination of FVIIa-sTF Inhibitors in Toxic Microcystis Cyanobacteria by LC-MS Technique
by: Andrea Roxanne J. Anas, et al.
Published: (2015-12-01)

Faktör VIII’e Karşı İnhibitör Gelişen Hemofili Hastalarında Dental Tedavi Yaklaşımı
by: Gulsum Ak, et al.
Published: (2011-01-01)

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
by: Johnny Mahlangu, et al.
Published: (2021-08-01)

TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity
by: Stavik Benedicte, et al.
Published: (2013-01-01)

FVIIa-sTF and Thrombin Inhibitory Activities of Compounds Isolated from Microcystis aeruginosa K-139
by: Andrea Roxanne J. Anas, et al.
Published: (2017-08-01)

Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients
by: Heng Joo Ng, et al.
Published: (2006-12-01)

Recombinant Activated Factor VII (rFVIIa/ NovoSeven®) In The Management Of Massive Bleeding In Hospital Universiti Sains Malaysia
by: Mohd Shah, Nurfatin
Published: (2017)

Use of Recombinant Activated Factor VIIa in a Six-Month-Old Child Due to Massive Hemorrhage During Elective Surgery for Choroid Plexus Carcinoma: Case Report
by: Alenka Spindler Vesel, et al.
Published: (2015-01-01)

Treatment of Swine Closed Head Injury with Perfluorocarbon NVX-428
by: Francoise Arnaud, et al.
Published: (2020-09-01)

Recombinant factor VIIa is associated with an improved 24-hour survival without an improvement in inpatient survival in massively transfused civilian trauma patients
by: Bartolomeu Nascimento, et al.
Published: (2011-01-01)

The Challenge of Hemorrhagic Shock Management During Low-Molecular-Weight Heparin Treatment
by: Morotti A, et al.
Published: (2020-03-01)

Effects of the Oxygen-Carrying Solution OxyVita C on the Cerebral Microcirculation and Systemic Blood Pressures in Healthy Rats
by: Rania Abutarboush, et al.
Published: (2014-11-01)

RECOMBINANT FACTOR VIIa – NEW TREATMENT OPTION FOR CONTROL OF INTRACTABLE BLEEDING IN SURGICAL AND TRAUMA PATIENTS AND IN OTHER HAEMOSTASIS DISORDERS
by: Samo Zver, et al.
Published: (2004-12-01)

Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience
by: Karla Rener, et al.
Published: (2023-11-01)

Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC)
by: Rajpurkar M, et al.
Published: (2019-09-01)

Eptacog Alfa (Activated) Is Physically and Chemically Stable over 24 Hours when Administered as Bolus Injections in an Automated Infusion Pump
by: Per Rexen, et al.
Published: (2019-01-01)

Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience
by: Giancarlo Castaman, et al.
Published: (2023-03-01)

Trauma-Induced Coagulopathy: Overview of an Emerging Medical Problem from Pathophysiology to Outcomes
by: Gabriele Savioli, et al.
Published: (2021-03-01)

Cerebral Microvascular and Systemic Effects Following Intravenous Administration of the Perfluorocarbon Emulsion Perftoran
by: Rania Abutarboush, et al.
Published: (2016-11-01)

Clinical utility of rotational thromboelastometry in detecting hemostatic disorders
by: Sabljić Nikica, et al.
Published: (2020-01-01)

First 20 years with recombinant FVIIa (NovoSeven).
by: Hedner, U, et al.
Published: (2011)